Maalox mini suspension for oral administration 4.3 g 6 pcs
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Algeldrat + Magnesium hydroxide
Release form
Suspension
Composition
1 mini-package: aldeldrat (aluminum hydroxide) (in the form of hydrated aluminum oxide) 460 mg, which corresponds to an aluminum oxide content of 230 mg, magnesium hydroxide 400 mg. Auxiliary substances: sucrose solution 64% - 4913 mg, sorbitol liquid (non-crystallizing) - 200 mg, xanthan gum - 2.4 mg, guar - 5.6 mg, black currant flavor - 13.2 mg, sodium chloride - 4.8 mg.
Pharmacological effect
Antacid, has no systemic action. Its antacid capacity is equal to 20 meq H + per mini-pack (in vitro determination according to the Rosset-Rice method). The drug neutralizes free hydrochloric acid without causing secondary hypersecretion of hydrochloric acid. In connection with the increase in pH when it is taken, the peptic activity of gastric juice decreases. It also has an adsorbing and enveloping effect, which reduces the impact of damaging factors on the mucous membrane of the stomach and duodenum. Maalox mini is able to eliminate or alleviate heartburn for several hours. Due to the balance of its composition in relation to the effect on the motility of the gastrointestinal tract, the Maalox mini usually does not cause constipation. Magnesium hydroxide and algaldrat pass x-rays.
Pharmacokinetics
Magnesium and aluminum hydroxides are considered to be local antacids that are practically not absorbed when taken orally at recommended doses.
Indications
- heartburn; - belching sour contents.
Contraindications
- hypersensitivity to active substances and other components of the drug; - severe renal failure; - hypophosphatemia; - sucrase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption (due to the presence of sorbitol and sucrose in the composition); age up to 15 years. With caution- Aluminum hydroxide can cause constipation, an overdose of magnesium salts can lead to a weakening of intestinal peristalsis; in high-risk patients (patients with renal insufficiency, elderly people), taking high doses of the drug can cause or aggravate intestinal obstruction and intestinal obstruction. - Aluminum hydroxide is poorly absorbed from the gastrointestinal tract, therefore patients with normal renal function have systemic effects rarely.Long-term treatment, the use of the drug in excessively high doses, or the use of the drug in standard doses against the background of reduced intake of phosphates from food can lead to phosphate deficiency (due to the binding of aluminum to phosphate), which is accompanied by increased bone resorption and hypercalciuria with the risk of osteomalacia . Patients at risk of developing phosphate deficiency or long-term use of the drug should be treated under medical supervision. - If kidney function is impaired (when taking Maalox mini in these patients, plasma concentrations of magnesium and aluminum can be increased, and with long-term use of Maalox mini in high doses, including and in high therapeutic doses, the development of encephalopathy, dementia, microcytic anemia or exacerbation of osteomalacia caused by dialysis is possible. - In patients with porphyria, n Catching up on gemodialize.- When illness Altsgeymera.- In diabetes (due to the connection with the content of the drug in the composition of sucrose) .- During pregnancy.
Precautionary measures
Do not exceed recommended doses.
Use during pregnancy and lactation
To date, no specific teratogenic effects have been identified with Maalox mini during pregnancy, however, due to insufficient clinical experience, its use in pregnancy is possible only in low doses, briefly and in cases where the potential benefit of therapy for the mother justifies the potential risk. for the fetus. When using the drug in accordance with the dosing regimen, the absorption of combinations of aluminum hydroxide and magnesium salts in the mother’s body is limited, therefore Maalox mini riznan compatible with breast vskarmlivaniem.V experimental animal studies received clear evidence for the presence of teratogenic effect in aluminum hydroxide and magnesium hydroxide.
Dosage and administration
The contents of 1-2 mini-packets are ingested through 1-1.5 hours after a meal or when heartburn occurs. If necessary, you can take an additional dose of the drug 2 hours after the previous dose. The maximum daily dose is 12 mini-packs.The course of treatment is no more than 2-3 months. For occasional use, for example, for discomfort after errors in the diet, take 1-2 mini-packs once. For mildly severe kidney failure, the maximum daily dose is 8 mini-packs. In moderately severe renal failure, the maximum daily dose is 6 mini-packets. Before opening the mini-packet, you should gently mix its contents, carefully flexing the bag between your fingers. Squeeze the contents of the package in a spoon or mouth (take the suspension without prior dilution).
Side effects
If the recommended dosing regimen is observed, the side effects are insignificant. The frequency of adverse effects (according to the WHO classification): infrequent (≥0.1% and <1%); frequency unknown (according to available data, it is impossible to estimate the frequency of occurrence). From the immune system: frequency unknown - hypersensitivity reactions, anaphylactic reactions. Allergic reactions: frequency unknown - itching, urticaria, angioedema. From the digestive system: infrequently - diarrhea constipation. On the part of the metabolism: the frequency is unknown - hypermagnesium, hyperaluminiemia, hypophosphatemia (with long-term treatment or taking in high doses, or when taken in standard doses with no phosphate content in food), which can lead to increased bone resorption, hypercalciuria, osteomalacia.
Overdose
Symptoms: diarrhea, abdominal pain and vomiting are possible. In patients at risk, taking high doses of the drug may cause or aggravate intestinal obstruction or intestinal obstruction. Treatment: aluminum and magnesium are excreted in the urine. Losses and forced diuresis are replenished. Patients with renal insufficiency need to undergo hemodialysis or peritoneal dialysis.
Interaction with other drugs
With simultaneous use with quinidine, it is possible to increase serum concentrations of quinidine and develop quinidine overdose. When taken simultaneously with Maalox mini, absorption of the following drugs from the gastrointestinal tract is decreased: histamine H2 receptor blockers, propranolol, atenolol, cefdinir, cefpodoxime, metoprolol, chloroquine, prostacyclin blockersdiflunisal, digoxin, bisphosphonates, ethambutol, isoniazid, fluoroquinolones, sodium fluoride, corticosteroids (described for prednisolone and dexamethasone), indomethacin, ketoconazole, lincosamides, antipsychotics of phenothiazine derivatives, penicillamine, rosuvastine, and rosuvatyastine In the case of a 2-hour interval between taking these drugs and Maalox mini and a 4-hour interval between taking fluoroquinolones and Maalox mini, in most cases this undesirable interaction can be avoided. When using Maalox mini with polystyrenesulfonate (kayeksalat) together, take caution from - due to the possible risk of reducing the effectiveness of potassium resin binding and the development of metabolic alkalosis in patients with renal insufficiency (for aluminum hydroxide and magnesium, iroxid) and intestinal obstruction (for aluminum hydroxide). When aluminum hydroxide is combined with citrates, it is possible to increase plasma concentrations of aluminum, especially in patients with renal insufficiency.
special instructions
If during treatment the symptoms of the gastrointestinal tract persist for more than 10 days or deterioration is observed, then the diagnosis should be clarified and treatment should be corrected. The 2-hour interval between using Maalox mini and other drugs should be observed. Despite the fact that the drug is released without a prescription, before using the drug during pregnancy and lactation (breastfeeding), as well as in adolescents over 15 years of age and patients with mild to moderate renal insufficiency, it is recommended consult vrachom.Sleduet avoid prolonged drug administration Maalox mini renal impairment. When prescribing the drug Maalox mini in patients with mild to moderate renal insufficiency, plasma concentrations of aluminum and magnesium should be carefully monitored, and if they are increased, the drug should be immediately discontinued. Algeldrate with a low phosphate content in the diet can lead to the development of phosphorus deficiency in the body . Therefore, in its application, especially long-lasting, it is necessary to ensure sufficient intake of phosphates from food. One mini-package of the drug contains 3.15 g of sucrose and 0.2 g of sorbitol,accordingly, the maximum daily dose contains 37.80 g of sucrose and 2.4 g of sorbitol. Influence on the ability to drive vehicles and control mechanisms The drug does not affect the ability to drive vehicles and work with mechanisms.